Skip to content

Clinical and Cost-effectiveness of Group Schema Therapy for Complex Eating Disorders: the GST-EAT Study

Clinical and Cost-effectiveness of Group Schema Therapy for Complex Eating Disorders: the GST-EAT Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05812950
Enrollment
230
Registered
2023-04-14
Start date
2023-07-24
Completion date
2026-12-31
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa, Atypical Anorexia Nervosa (Other Specified Eating Disorder), Bulimia Nervosa, Atypical Bulimia Nervosa (Other Specified Eating Disorder)

Keywords

CBT-E, Group Schema Therapy, Eating disorders, Effectiveness

Brief summary

Amongst psychiatric illnesses, eating disorders (EDs) are notoriously difficult to treat and have a high mortality rate. The average duration of an ED is 6 years and for a majority of ED patients, the disorder will become chronic. Comorbid personality pathology such as negative core beliefs and early maladaptive schemas (EMS) are strongly related to ED severity and chronicity. Enhanced cognitive-behavioural therapy for eating disorders (CBT-E) is used as the first line transdiagnostic treatment for EDs. However, CBT-E is mainly symptom-focused and does not tap into these underlying core beliefs and EMS. Given the limited treatment effects of existing ED treatments, and the importance of comorbid personality pathology, there is an urgent need to examine more effective treatments for EDs. Group-schematherapy (GST) overcomes the limitations of CBT-E and preliminary results for treatment-resistant EDs are promising. However, robust evidence regarding the clinical and cost-effectiveness of GST for patients that do not benefit from CBT-E is not yet available. The central aim of this project is to investigate the clinical and cost-effectiveness of GST for EDs in patients with comorbid personality pathology, who do not show a clinically significant response in the first phase of CBT-E. This is relevant and important as studies examining the effectiveness of GST for EDs are scarce. This project is a joint research initiative of three academic centers (Dutch Universities), four large nation-wide mental health organizations, and two foundations for client empowerment and participation. Eligible patients will be randomized to either GST or continuation of their CBT-E treatment after failing to show a significant treatment response in the first phase of CBT-E. Based on encouraging findings from previous studies and our own pilot data, a statistically and clinically significant better outcome in terms of ED symptoms, negative core beliefs, EMS, schema modes, and quality of life is expected in the GST group compared to the CBT-E group. GST is also expected to be more cost-effective compared to CBT-E as GST may in the long run prevent chronicity in terms of long treatment trajectories and delayed recovery. Finally, with the proviso of good results for GST, we will disseminate and implement GST in the standard of care for EDs. This project thereby has great potential to improve clinical and cost-effectiveness of treatment for chronic EDs.

Interventions

BEHAVIORALGST

Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)

BEHAVIORALCBT-E

Outpatient eating disorder treatment (20-40 weekly individual sessions)

Sponsors

Utrecht University
CollaboratorOTHER
ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
GGNet Amarum
CollaboratorUNKNOWN
GGZ Breburg
CollaboratorOTHER
Accare
CollaboratorOTHER
Co-eur
CollaboratorUNKNOWN
GGZ Friesland
CollaboratorOTHER
University of Groningen
CollaboratorOTHER
Maastricht University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Once data collection is complete, the data will be blinded by one of the principal investigators. This allows for blinded analysis by the outcome assessor.

Intervention model description

All participants start with CBT-E phase 1 and 2. If not improved enough with regard to eating disorder symptoms (following EDE-Q pre- and post measure comparison) in the first phase, they will be included in the RCT. When included they will be randomly assigned to either the CBT-E continuation condition or the GST condition.

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\) age \> 16 years; * 2\) a DSM-5 diagnosis of anorexia nervosa, bulimia nervosa, or other specified ED (atypical anorexia nervosa or bulimia nervosa with a low frequency or limited duration).

Exclusion criteria

* 1\) not being able to speak and read the Dutch language; * 2\) being in an acute psychotic mental health state at the start of the study; * 3\) being diagnosed with an autism spectrum disorder; * 4\) having an IQ below 80, as determined with a validated instrument; * 5\) showing an early response after phase 1 of CBT-E.

Design outcomes

Primary

MeasureTime frameDescription
Change in Eating Disorder Examination Questionnaire (EDE-Q) scoreBaseline (Before start CBT-E), 4 weeks (8 sessions CBT-E), end of treatment (up to 39 weeks after randomization), and 6 and 12 months after end of treatmentEating pathology will be measured with the Eating Disorder Examination Questionnaire (EDE-Q). Fairburn & Beglin, 2008). This self-report measure is the most commonly used routine outcome measure in ED facilities in the Netherlands to measure the severity of the ED.

Secondary

MeasureTime frameDescription
Change in Young Schema Questionnaire Short Form version 3 3 (YSQ-S3) scoreBaseline (Before start CBT-E), end of treatment (up to 39 weeks after randomization), and 6 and 12 months after end of treatmentThe YSQ-S3 will be used to measure 18 early maladaptive schemas and is a valid instrument for the assessment of early maladaptive schemas in clinical and research settings.
Change in Schema Mode Inventory for Eating Disorders (SMI-ED) score4 weeks (8 sessions CBT-E), end of treatment (up to 39 weeks after randomization), and 6 and 12 months after end of treatmentThe SMI-ED will be used to assess schema modes that are relevant in patients with an eating disorder. It measures 5 maladaptive child modes, 2 maladaptive internalized/introject modes, 7 maladaptive coping modes, and 2 healthy factors.
Change in Brief Symptom Inventory (BSI) score4 weeks (8 sessions CBT-E), end of treatment (up to 39 weeks after randomization), and 6 and 12 months after end of treatmentThe BSI will be used to assess general psychological and physical symptoms
Change in Eating Disorder Quality of Life (EDQoL) score4 weeks (8 sessions CBT-E), end of treatment (up to 39 weeks after randomization), and 6 and 12 months after end of treatmentQuality of life will be assessed using the EDQoL
Childhood Trauma Questionnaire-Short Form (CTQ-SF)Baseline (Before start CBT-E)This questionnaire consists of 28 questions measuring physical abuse, emotional abuse, sexual abuse, physical neglect and emotional neglect during childhood.
Session Rating Scale (SRS)up to 39 weeksTherapeutic alliance will be evaluated in each session using the patient-rated SRS, which is a short (four items) measure.
Quality of life and achievement personalized treatment goalsEnd of treatment (up to 39 weeks after randomization)A qualitative interview (to be developed)
Treatment Inventory of Costs in Patients with psychiatric disorders (TiC-P)4 weeks (8 sessions CBT-E), end of treatment (up to 39 weeks after randomization), and 6 and 12 months after end of treatmentPatient-reported productivity losses and multiple dimensions of healthcare resource consumption will be measured, using the validated TIC-P questionnaire. This questionnaire has been tested extensively for patients with a psychiatric disorder, using a recall period of three months. Using various unit prices in healthcare, both productivity losses and healthcare resource consumption will be valued monetarily in order to estimate the actual costs for the CBT-E arm and the GST arm within a closed time frame (Bouwmans et al., 2013).
Change in Quality-adjusted life years score4 weeks (8 sessions CBT-E), end of treatment (up to 39 weeks after randomization), and 6 and 12 months after end of treatmentFive dimensions of quality of life will be measured, using the EQ-5D-5L questionnaire: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Participants will be asked to rank the extent to which they feel satisfied about these five dimensions on a 5-point Likert scale. Then they will be asked to rank their current health state, using a 0-100 VAS analog scale. Final utility scores from both the CBT-E arm and the GST arm on all dimensions of this questionnaire will be converted into a single health utility measure: Quality-adjusted life years or QALYs (Feng et al., 2021).
Clinical Perfectionism Questionnaire (CPQ)Baseline (Before start CBT-E)The CPQ will be used to assess clinical perfectionism. This questionnaire consists of 12 items that measure the level of self-evaluation based on striving towards extremely high personal standards despite adverse consequences.

Countries

Netherlands

Contacts

Primary ContactJeffrey Roelofs, Dr.
j . roelofs @ maastricht university . nl+31433881607
Backup ContactSuzanne Mares, Dr.
s.mares@ggnet.nl+31688 933 5701

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026